APOE-associated disease risk and sex-specific effects in Egyptian Alzheimer's disease: an exploratory study
Mai Othman1, Eman Khedr2, Shimaa Heikal1
1Institute of Global Health and Human Ecology (I-GHHE) The American University in Cairo Cairo Egypt.
Introduction:
The apolipoprotein E (APOE) gene is the strongest known genetic risk factor for late-onset Alzheimer's disease (AD), particularly the ε4 allele. Evidence suggests that women carrying at least one APOE ε4 allele have a higher risk of developing AD compared to men. However, data addressing genetic risk and sex-specific effects in Middle Eastern and North African populations remain limited.
Methods:
To address this gap, we evaluated APOE allele frequencies, their association with AD risk, and their contribution to sex-specific variability in a cohort of 63 clinically diagnosed AD patients and 201 cognitively healthy controls recruited across Egypt.
Results:
The APOE ε3 allele was the most prevalent in both AD cases (83.3%) and controls (83.6%). The ε4 allele was more frequent among AD patients (12.7%) than controls (8.0%) (adjusted odds ratio [OR] = 1.09, 95% confidence interval [CI]: 0.46 to 2.49, p = 0.85), while the ε2 allele was less frequent in AD patients (4.0%) compared to controls (8.5%) (adjusted OR = 0.82, 95% CI: 0.24 to 2.36, p = 0.73). However, neither association reached statistical significance after Benjamini-Hochberg false discovery rate correction. Sex-stratified analyses revealed no significant sex-specific effects of APOE alleles.
Conclusion:
This pilot study provides the first characterization of APOE genotype and allele frequencies in Egyptians with clinically confirmed AD. No statistically significant association was observed between APOE status and AD risk in either males or females. Larger, geographically representative studies are needed to further elucidate the role of APOE in AD susceptibility within the Egyptian population and to explore potential alternative genetic or environmental contributors.
More Related Videos
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
04:22Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles
Published on: May 20, 2024
Related Concept Videos
Alzheimer Disease l: Introduction
Amebiasis
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology
Dementia l: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
